US antitrust officials aren’t satisfied with Halliburton proposals for clearing its purchase of oil services rival Baker Hughes Inc. and don’t expect to announce until next year whether it blesses a deal, according to a person familiar with the situation.
The companies previously agreed to an extension until Tuesday with the Justice Department over the proposed $26 billion merger. The US antitrust officials aren’t obligated to complete their review by today, said the person, who declined to be named because the review is confidential.
The companies can’t close their deal because antitrust officials in Europe, Australia and Brazil are also reviewing how the merger of the world’s No. 2 and No. 3 oil-servicing companies could change the competitive landscape.
When it announced plans to acquire Baker Hughes in November 2014 — a deal valued at $34.6 billion in cash and stock deal at the time — Halliburton said it would divest assets with revenue of as much as $7.5 billion. General Electric Co. is in advanced talks to buy the drill-bits and drilling-services divisions of Halliburton, and is exploring bids for other assets, Bloomberg News reportedearlier this month.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan